Abbott to cut primary care sales reps

Share this article:
Abbott Laboratories plans to eliminate “several hundred” primary care sales representative jobs across the US, a company spokesman confirmed.

The cuts are related to the company’s 2006 acquisition of Kos Pharmaceuticals for $3.7 billion, according to Scott Stoffel, Abbott spokesman.

“We’ve been working to integrate the Kos sales force with Abbott’s primary care sales force,” Stoffel told MM&M. “We used an analysis based on factors like historical performance, product expertise and geography to create a new combined pharmaceutical primary care sales organization that will best serve our customers and eliminate duplications.”

Sales reps affected by the cuts were informed in February and March, according to Stoffel.

Abbott plans to eliminate 200 scientist jobs at its Lake County, IL, facilities as part of its decision to phase out its development of drugs for metabolic diseases.

“We’re going to be focusing on fewer specific diseases, which we feel will better position Abbott to discover andadvance medications,” Stoffel said.

Abbott agreed to buy specialty firm Kos for $3.7 billion in November, a move complementing its cardiovascular franchise and boosts its pipeline.  

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...